HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
13.59
+0.14 (1.04%)
At close: Apr 28, 2026, 4:00 PM EDT
13.60
+0.01 (0.07%)
After-hours: Apr 28, 2026, 4:10 PM EDT
HUTCHMED (China) Employees
HUTCHMED (China) had 1,796 employees as of December 31, 2025. The number of employees decreased by 15 or -0.83% compared to the previous year.
Employees
1,796
Change (1Y)
-15
Growth (1Y)
-0.83%
Revenue / Employee
$305,408
Profits / Employee
$254,404
Market Cap
2.35B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,300 |
| Perrigo Company | 8,100 |
| Phibro Animal Health | 2,475 |
| ANI Pharmaceuticals | 970 |
| Supernus Pharmaceuticals | 778 |
| Prestige Consumer Healthcare | 600 |
| BioCryst Pharmaceuticals | 435 |
| Harrow | 373 |
HCM News
- 20 days ago - HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 - GlobeNewsWire
- 5 weeks ago - HUTCHMED Initiates And Doses First Patient In Phase III Trial Of HMPL-760 For R/R DLBC Lymphoma - Nasdaq
- 5 weeks ago - HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China - GlobeNewsWire
- 6 weeks ago - HUTCHMED (China) Ltd (HCM) Shares Up 3.67% on Mar 16 - GuruFocus
- 6 weeks ago - HUTCHMED (China) Ltd (HCM) Full Year 2025 Earnings Call Highlights: Strong Global Expansion and ... - GuruFocus
- 6 weeks ago - HUTCHMED (China) Ltd (HCM) Trading 4.6% Higher on Mar 11 - GuruFocus
- 7 weeks ago - Hutchmed (HCM) Withdraws Tazverik from China Amid U.S. Market Recall - GuruFocus
- 7 weeks ago - HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China - GlobeNewsWire